Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT201 in Advanced Lung Cancer
NCT06519669Terminated
- Sponsor
- Grit Biotechnology
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Open-label, single-arm trial of GT201 in lung cancer, sponsored by Grit Biotechnology. Primary endpoints: Objective Response Rate at 3 years and Incidence and severity of adverse events per CTCAE 5.0 at 3 years. Started Jul 2024; status: terminated.
02
Drugs
GT201
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT06519669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519669.